Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2015-10-05 Board/Management Inform…
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 1% confidence The document is a press release announcing that Marie Bézenger has joined DEINOVE as the Director of Operations and joined the Executive Committee. This announcement details a change in senior management personnel. According to the definitions, documents announcing changes in the company's board of directors or senior management fall under the 'Board/Management Information' category, which corresponds to the code MANG.
2015-10-05 English
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a "technological and commercial partnership" between two companies (DEINOVE and Tyton BioEnergy Systems). It details the nature of the agreement, quotes executives, and provides boilerplate 'About' sections for both entities. This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (like IR or AR), is best classified as a general announcement. Since it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements that are not covered by more specific codes.
2015-09-08 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release ("Communiqué de presse") dated September 8, 2015, announcing a technological and commercial partnership between DEINOVE and Tyton BioEnergy Systems regarding the production of bio-sourced compounds using engineered bacteria and energy tobacco. This type of announcement, detailing strategic business developments, partnerships, and technology collaborations, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR, or DIV). It is a general corporate announcement regarding business strategy and operations. Since it is not a formal regulatory filing like a 10-K or a specific financial event report, the most appropriate fallback category is 'Regulatory Filings' (RNS) for general corporate news releases that don't match other specific codes, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. Given the options, RNS serves as the best general corporate announcement category for non-standard filings.
2015-09-08 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a scientific/technical achievement (producing muconic acid from 2G substrates) and provides context about the company's technology and future markets. This is a general corporate announcement, not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed quarterly report (IR). It is a general corporate communication. Since it doesn't fit the specific categories like AGM-R, 10-K, ER, IR, or CT, and it is a formal announcement, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or significant corporate announcements that aren't covered by the more specific codes.
2015-09-02 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is titled 'Press Release' and announces a specific scientific/production achievement: 'DEINOVE PRODUCES MUCONIC ACID FROM 2G SUBSTRATES'. It details R&D progress, production increases, and quotes the CEO regarding industrial applications. This format—a brief announcement of operational or scientific news, often released outside of mandatory financial reporting cycles—is characteristic of a general press release. Since there is no specific regulatory form mentioned (like 10-K, DEF 14A, etc.), and it is not a transcript (CT), a formal financial report (IR, AR), or a management discussion (MDA), the most appropriate classification is the general regulatory/announcement fallback category, RNS (Regulatory Filings), as it serves as a public disclosure of material, non-financial operational news.
2015-09-02 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated July 21, 2015, announcing that DEINOVE has completed proof of concept for a bio-based muconic acid production program and is launching a new R&D platform. It details the technical advantages, market potential, and strategic rationale for this development. This type of announcement, focusing on a specific business development, R&D milestone, or strategic initiative, is best classified as a general business update or announcement. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific capital/dividend announcement, it falls under the general category for corporate news that doesn't fit elsewhere, which is Regulatory Filings (RNS) as the fallback for miscellaneous announcements, or potentially Investor Presentation (IP) if it were structured as a slide deck, but here it reads like a news release. Given the options, and that it is a substantive announcement of a new program rather than just a notice of a report being available (RPA), RNS is the most appropriate general category for corporate news releases that aren't earnings or capital structure specific.
2015-07-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.